§ — Researched for · Skin, hair & pigmentation
Topical GHK-Cu is a legitimate cosmetic ingredient with small controlled trials behind it. Everything beyond that — injectable copper peptide, melanotan II for tanning — is either unstudied or subject to explicit FDA warnings, and the approved tanning-pathway drug, afamelanotide, is restricted to a rare genetic disease.
Reviewed September 2026 · Sources: FDA, EMA
02 — What is being studied
Two distinct fields sit under one heading. Dermal matrix research studies copper tripeptide applied topically, with endpoints such as collagen density, wrinkle depth and photodamage measured in small controlled cosmetic trials. Pigmentation research studies melanocortin receptor agonists, where the measurable endpoint is melanin density and, in the approved case of afamelanotide, pain-free light exposure in erythropoietic protoporphyria.
The claims that travel furthest are the ones with the least behind them: systemic anti-aging from injected copper peptide, and hair regrowth. Neither has controlled human data. Melanotan II is not approved in any jurisdiction and has an adverse-event record including changing moles, nausea and reports of melanoma, which is why regulators have issued direct consumer warnings rather than reviewing it for compounding.
03 — The table
| Peptide | Researched for | Evidence | Regulatory status | As of |
|---|---|---|---|---|
| GHK-Cu | Skin aging, wound healing, hair growth, gene expression modulation. | B | Not an approved drug. Widely used as a cosmetic ingredient in topical products, which is regulated as a cosmetic, not a drug. Injectable use is not approved and its compounding status must be verified. | 2026-09-06 |
| Melanotan II | Skin tanning, erectile dysfunction (abandoned development). | D | Not FDA-approved; FDA has issued consumer warnings. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it. | 2026-09-06 |
04 — Per peptide
Regulatory status · United States · as of September 2026
Not an approved drug. Widely used as a cosmetic ingredient in topical products, which is regulated as a cosmetic, not a drug. Injectable use is not approved and its compounding status must be verified.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forSkin aging, wound healing, hair growth, gene expression modulation.
Full profile: GHK-Cu →Regulatory status · United States · as of September 2026
Not FDA-approved; FDA has issued consumer warnings. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forSkin tanning, erectile dysfunction (abandoned development).
Full profile: Melanotan II →05 — What the data does not show
Systemic anti-aging or hair regrowth by injection has not been shown; safe tanning via melanotan II has been contradicted by adverse-event reports.
06 — Questions for your physician
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.